Benzinga | Nov 19, 2020 07:46AM EST

Citigroup Initiates Coverage On Arrowhead Pharmaceuticals with Buy Rating, Announces Price Target of $90

Citigroup analyst Shawn Egan initiates coverage on Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy rating and announces Price Target of $90.